Clinical Trial

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 1, 2026 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of SYS6010 versus platinum-based chemotherapy in participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-07; most recent amendment 2026-06-29.
Status change: Not Yet Recruiting → Recruiting 2025-11-13
Trial Details
NCT Number NCT06927986
Lead Sponsor CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions EGFR-mutated Locally Advanced or Metastatic NSCLC
Enrollment 380 participants
Start Date 2025-03-30
Primary Completion 2026-07-30 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-01